-
Something wrong with this record ?
Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
L. Pazdera, JM. Cohen, X. Ning, VR. Campos, R. Yang, P. Pozo-Rosich
Language English Country Great Britain
Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- MeSH
- Adult MeSH
- Double-Blind Method MeSH
- Middle Aged MeSH
- Humans MeSH
- Migraine Disorders drug therapy prevention & control MeSH
- Adolescent MeSH
- Young Adult MeSH
- Antibodies, Monoclonal administration & dosage therapeutic use MeSH
- Treatment Failure MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase III MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
OBJECTIVE: To evaluate the efficacy of monthly or quarterly fremanezumab in patients with chronic migraine or episodic migraine and documented inadequate response to 2, 3, or 4 classes of prior migraine preventive medications. METHODS: This is an exploratory analysis of a randomized, double-blind, placebo-controlled, phase 3b trial for patients with chronic migraine or episodic migraine and inadequate response to 2 to 4 prior migraine preventive medication classes randomized (1:1:1) to fremanezumab (quarterly or monthly) or placebo. In this exploratory analysis, changes from baseline in the monthly average number of migraine days during 12 weeks of double-blind treatment and adverse events were evaluated for predefined subgroups of patients by number of prior preventive medication classes with inadequate response. RESULTS: Overall, 414, 265, and 153 patients had inadequate response to 2, 3, and 4 preventive medication classes, respectively. Changes from baseline in monthly average migraine days during 12 weeks were significantly greater with fremanezumab compared with placebo for patients with documented inadequate response to 2 classes (least-squares mean difference vs placebo [95% confidence interval]: quarterly, -2.9 [-3.83, -1.98]; monthly, -3.7 [-4.63, -2.75]), 3 classes (quarterly, -3.3 [-4.65, -1.95]; monthly, -3.0 [-4.25, -1.66]), and 4 classes (quarterly, -5.3 [-7.38, -3.22]; monthly, -5.4 [-7.35, -3.48]) of migraine preventive medications (all p < 0.001). No significant treatment-by-subgroup interactions were observed for any outcome (p interaction > 0.20 for all). Adverse events were comparable for placebo and fremanezumab. CONCLUSION: Significant improvements in efficacy were observed with fremanezumab compared with placebo, even in patients who had previously experienced inadequate response to 4 different classes of migraine preventive medications.ClinicalTrials.gov identifier: NCT03308968.
Headache Unit Neurology Department Vall d'Hebron University Hospital Barcelona Spain
Teva Branded Pharmaceutical Products R and D Inc West Chester PA USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22003793
- 003
- CZ-PrNML
- 005
- 20220127145846.0
- 007
- ta
- 008
- 220113s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/03331024211008401 $2 doi
- 035 __
- $a (PubMed)33990144
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Pazdera, Ladislav $u Vestra Clinics, Rychnov nad Kněžnou, Czech Republic
- 245 10
- $a Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response / $c L. Pazdera, JM. Cohen, X. Ning, VR. Campos, R. Yang, P. Pozo-Rosich
- 520 9_
- $a OBJECTIVE: To evaluate the efficacy of monthly or quarterly fremanezumab in patients with chronic migraine or episodic migraine and documented inadequate response to 2, 3, or 4 classes of prior migraine preventive medications. METHODS: This is an exploratory analysis of a randomized, double-blind, placebo-controlled, phase 3b trial for patients with chronic migraine or episodic migraine and inadequate response to 2 to 4 prior migraine preventive medication classes randomized (1:1:1) to fremanezumab (quarterly or monthly) or placebo. In this exploratory analysis, changes from baseline in the monthly average number of migraine days during 12 weeks of double-blind treatment and adverse events were evaluated for predefined subgroups of patients by number of prior preventive medication classes with inadequate response. RESULTS: Overall, 414, 265, and 153 patients had inadequate response to 2, 3, and 4 preventive medication classes, respectively. Changes from baseline in monthly average migraine days during 12 weeks were significantly greater with fremanezumab compared with placebo for patients with documented inadequate response to 2 classes (least-squares mean difference vs placebo [95% confidence interval]: quarterly, -2.9 [-3.83, -1.98]; monthly, -3.7 [-4.63, -2.75]), 3 classes (quarterly, -3.3 [-4.65, -1.95]; monthly, -3.0 [-4.25, -1.66]), and 4 classes (quarterly, -5.3 [-7.38, -3.22]; monthly, -5.4 [-7.35, -3.48]) of migraine preventive medications (all p < 0.001). No significant treatment-by-subgroup interactions were observed for any outcome (p interaction > 0.20 for all). Adverse events were comparable for placebo and fremanezumab. CONCLUSION: Significant improvements in efficacy were observed with fremanezumab compared with placebo, even in patients who had previously experienced inadequate response to 4 different classes of migraine preventive medications.ClinicalTrials.gov identifier: NCT03308968.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a monoklonální protilátky $x aplikace a dávkování $x terapeutické užití $7 D000911
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a migréna $x farmakoterapie $x prevence a kontrola $7 D008881
- 650 _2
- $a neúspěšná terapie $7 D017211
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Cohen, Joshua M $u Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA
- 700 1_
- $a Ning, Xiaoping $u Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA
- 700 1_
- $a Campos, Verena Ramirez $u Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA
- 700 1_
- $a Yang, Ronghua $u Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA
- 700 1_
- $a Pozo-Rosich, Patricia $u Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain $u Headache and Neurological Pain Research Group, Vall d'Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
- 773 0_
- $w MED00001084 $t Cephalalgia : an international journal of headache $x 1468-2982 $g Roč. 41, č. 10 (2021), s. 1075-1088
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33990144 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145842 $b ABA008
- 999 __
- $a ok $b bmc $g 1751298 $s 1154942
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 41 $c 10 $d 1075-1088 $e 20210514 $i 1468-2982 $m Cephalalgia $n Cephalagia $x MED00001084
- LZP __
- $a Pubmed-20220113
